

Claims

- 1 A method of treating wounds in a patient which comprises treating the
patient with an effective amount of a cGMP PDE5 inhibitor, or a
5 pharmaceutical composition thereof, wherein the wound type is selected
from: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and
acute wounds.
- 2 The use of a cGMP PDE5 inhibitor for the manufacture of a medicament
10 for the treatment of wounds, selected from the following types: chronic
venous ulcers, chronic arterial ulcers, chronic decubitus and acute
wounds.
- 3 A method or use as claimed in claim 1 or 2, wherein the inhibitor is
15 administered orally or topically.
- 4 A method or use as claimed in any preceding claim, wherein the wherein
the inhibitor has an IC50 at less than 100 nanomolar.
- 20 5 A method or use as claimed in claim 4, wherein the inhibitor has a
selectivity ratio in excess of 1000.
- 6 A method or use as claimed in any preceding claim, wherein the inhibitor
is sildenafil.
- 25 7 A method or use as claimed in claim 6, wherein the daily dosage is 5 to
500 mg.
- 8 A method or use as claimed in claim 7, wherein the daily dosage is 10 to
30 100 mg.

- 9 The use of a cGMP PDE5 inhibitor in combination with a matrix metalloprotease inhibitor (MMP), and/or a urokinase type plasminogen activator inhibitor (uPA), for the manufacture of a medicament for the treatment of wounds, selected from the following types: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and acute wounds.
- 5
- 10 Use as claimed in claim 9, wherein the MMP is selected from the group comprising: inhibitors of MMP-3, MMP-12 and MMP-13.
- 10 11 A pharmaceutical pack comprising: a pharmaceutical composition comprising a PDE5 inhibitor, directions relating to the use of the composition for treating wounds, and a container.
- 12 A combination of a PDE5 inhibitor together with a matrix metalloprotease inhibitor (MMP) and/or a urokinase type plasminogen activator inhibitor (uPA).
- 15
- 13 A combination as claimed in claim 12, wherein the MMP is selected from the group comprising: inhibitors of MMP-3, MMP-12 and MMP-13.